I-Mab (IMAB) News Today → Man who Predicted Trump 2016 Win: “Prepare for Election Meltdown” (From Paradigm Press) (Ad) Free IMAB Stock Alerts $1.88 +0.01 (+0.53%) (As of 06/7/2024 ET) Add Compare Share Share HeadlinesStock AnalysisAnalyst ForecastsChartCompetitorsFinancialsHeadlinesOptions ChainOwnershipSEC FilingsShort InterestTrendsStock AnalysisAnalyst ForecastsChartCompetitorsFinancialsHeadlinesOptions ChainOwnershipSEC FilingsShort InterestTrends All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative June 5 at 7:00 AM | prnewswire.comI-Mab Announces Collaboration with Bristol Myers Squibb to Evaluate Givastomig in a Combination Study for Newly Diagnosed Gastric and Esophageal CancersMay 24, 2024 | marketbeat.comI-Mab (NASDAQ:IMAB) Trading Down 0.6%I-Mab (NASDAQ:IMAB) Shares Down 0.6%May 23, 2024 | globenewswire.comI-Mab Announces Encouraging Phase 1 Clinical Data of PD-L1x4-1BB Bispecific Antibody Ragistomig at ASCO 2024May 22, 2024 | prnewswire.comI-Mab to Participate at the Jefferies Global Healthcare ConferenceApril 30, 2024 | prnewswire.comI-MAB Filed 2023 Annual Report on Form 20-FApril 16, 2024 | msn.comOmega Therapeutics CFO Joshua Reed to departApril 16, 2024 | marketbeat.comI-Mab (NASDAQ:IMAB) Short Interest UpdateI-Mab (NASDAQ:IMAB - Get Free Report) was the recipient of a large increase in short interest during the month of March. As of March 31st, there was short interest totalling 1,170,000 shares, an increase of 7.3% from the March 15th total of 1,090,000 shares. Based on an average daily volume of 436,300 shares, the days-to-cover ratio is presently 2.7 days.April 12, 2024 | markets.businessinsider.comI-MAB Buy Rating Justified by Strong Leadership and Promising PipelineApril 12, 2024 | marketbeat.comNeedham & Company LLC Reaffirms Buy Rating for I-Mab (NASDAQ:IMAB)Needham & Company LLC restated a "buy" rating and set a $6.00 target price on shares of I-Mab in a research report on Friday.April 5, 2024 | prnewswire.comI-Mab to Participate at the 23rd Annual Needham Virtual Healthcare ConferenceApril 4, 2024 | investing.comI-Mab completes divestiture of its Shanghai unit for $80 millionApril 2, 2024 | uk.finance.yahoo.comI-Mab Announces Closing of the Divestiture of Business Operations in ChinaApril 2, 2024 | prnewswire.comI-Mab Announces Closing of the Divestiture of Business Operations in ChinaMarch 20, 2024 | marketbeat.comI-Mab Expected to Post FY2025 Earnings of ($1.75) Per Share (NASDAQ:IMAB)I-Mab (NASDAQ:IMAB - Free Report) - HC Wainwright raised their FY2025 earnings per share (EPS) estimates for shares of I-Mab in a research note issued on Monday, March 18th. HC Wainwright analyst A. Fein now anticipates that the company will post earnings of ($1.75) per share for the year, up froMarch 18, 2024 | marketbeat.comHC Wainwright Reaffirms Buy Rating for I-Mab (NASDAQ:IMAB)HC Wainwright reissued a "buy" rating and issued a $8.00 price objective (down from $18.00) on shares of I-Mab in a research note on Monday.March 18, 2024 | finance.yahoo.comI-Mab Full Year 2023 Earnings: Revenues Beat Expectations, EPS LagsMarch 14, 2024 | finance.yahoo.comI-Mab Reports Full Year 2023 Financial Results and Business UpdateFebruary 22, 2024 | benzinga.comI-MAB Stock (NASDAQ:IMAB), Short Interest ReportFebruary 18, 2024 | seekingalpha.comI-Mab: Trading Below Net Cash With Multiple Upside OptionsFebruary 7, 2024 | marketwatch.comI-Mab to Divest Chinese Unit for Up to $80MFebruary 7, 2024 | msn.comI-Mab to divest Chinese assets amid rising geopolitical tensionsFebruary 7, 2024 | finance.yahoo.comI-Mab Signs Agreement to Divest its Assets and Business Operations in ChinaJanuary 31, 2024 | marketbeat.comI-Mab (NASDAQ:IMAB) Sees Significant Decline in Short InterestI-Mab (NASDAQ:IMAB - Get Free Report) saw a large decrease in short interest in January. As of January 15th, there was short interest totalling 1,510,000 shares, a decrease of 6.8% from the December 31st total of 1,620,000 shares. Based on an average trading volume of 635,700 shares, the short-interest ratio is currently 2.4 days.January 11, 2024 | msn.comAsian Equities Traded in the US as American Depositary Receipts Advance in Thursday TradingDecember 31, 2023 | uk.finance.yahoo.comI-Mab (IMAB) interactive stock chart – Yahoo FinanceDecember 28, 2023 | benzinga.comI-MAB Stock (NASDAQ:IMAB) Dividends: History, Yield and DatesDecember 21, 2023 | marketbeat.comI-Mab Expected to Earn FY2023 Earnings of ($1.85) Per Share (NASDAQ:IMAB)I-Mab (NASDAQ:IMAB - Free Report) - Stock analysts at Cantor Fitzgerald issued their FY2023 earnings per share estimates for shares of I-Mab in a report issued on Monday, December 18th. Cantor Fitzgerald analyst L. Chen anticipates that the company will post earnings per share of ($1.85) for theDecember 21, 2023 | marketbeat.comI-Mab (NASDAQ:IMAB) Given Overweight Rating at Cantor FitzgeraldCantor Fitzgerald restated an "overweight" rating on shares of I-Mab in a report on Monday.November 19, 2023 | finance.yahoo.comIndividual investors account for 41% of I-Mab's (NASDAQ:IMAB) ownership, while private equity firms account for 26%November 6, 2023 | finance.yahoo.comI-Mab Announces Participation at Jefferies and Piper Conferences in NovemberNovember 2, 2023 | msn.comI-Mab gains FDA breakthrough tag for kidney disease therapyNovember 2, 2023 | markets.businessinsider.comI-Mab:Felzartamab Granted Breakthrough Therapy Designation By FDA For Primary Membranous NephropathyNovember 2, 2023 | finance.yahoo.comFelzartamab Granted Breakthrough Therapy Designation by U.S. Food and Drug Administration (FDA) for Primary Membranous Nephropathy (PMN)November 1, 2023 | finance.yahoo.comI-Mab Announces Poster Presentations of 4-1BB Bispecific Antibody Portfolio at SITC 2023October 16, 2023 | finance.yahoo.comI-Mab Announces Phase 1 Data of Givastomig at ESMO 2023October 10, 2023 | finance.yahoo.comI-Mab and ABL Bio Announce Latest Updates of PD-L1 and 4-1BB Bispecific Antibody TJ-L14B/ABL503October 5, 2023 | insidermonkey.comRay Dalio on Potential US China War and Rise of ChinaSeptember 25, 2023 | markets.businessinsider.comExpert Ratings for I-MABSeptember 25, 2023 | nasdaq.comNeedham Maintains I-Mab - ADR (IMAB) Buy RecommendationSeptember 22, 2023 | finance.yahoo.comUPDATE 1-AbbVie terminates deal with I-Mab to develop cancer drugSeptember 13, 2023 | msn.comI-Mab: Why This Company Trades At A Third The Value Of Its CashSeptember 5, 2023 | markets.businessinsider.comWhere I-MAB Stands With AnalystsSeptember 3, 2023 | uk.finance.yahoo.comI-Mab (IMAB) stock historical prices & data – Yahoo FinanceSeptember 1, 2023 | marketbeat.comShort Interest in I-Mab (NASDAQ:IMAB) Rises By 7.9%I-Mab (NASDAQ:IMAB - Get Free Report) was the recipient of a large increase in short interest in August. As of August 15th, there was short interest totalling 1,640,000 shares, an increase of 7.9% from the July 31st total of 1,520,000 shares. Based on an average daily volume of 344,900 shares, the days-to-cover ratio is currently 4.8 days.August 20, 2023 | marketbeat.comBarclays PLC Boosts Stock Holdings in I-Mab (NASDAQ:IMAB)Barclays PLC increased its position in shares of I-Mab (NASDAQ:IMAB - Free Report) by 30.7% during the first quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 430,406 shares of the company's stock after buying an additional 101,106 shares during tAugust 19, 2023 | msn.comCantor Fitzgerald Reiterates I-Mab - ADR (IMAB) Overweight RecommendationAugust 18, 2023 | markets.businessinsider.comAnalyst Ratings for I-MABAugust 18, 2023 | insidermonkey.comI-Mab (NASDAQ:IMAB) Q2 2023 Earnings Call TranscriptAugust 18, 2023 | marketbeat.comI-Mab (NASDAQ:IMAB) Stock Rating Reaffirmed by Cantor FitzgeraldCantor Fitzgerald restated an "overweight" rating and issued a $25.00 target price on shares of I-Mab in a research note on Friday.August 17, 2023 | seekingalpha.comI-Mab Biopharma Non-GAAP EPADS of -$1.05 misses by $0.26, revenue of $2.7M misses by $0.3M Get I-Mab News Delivered to You Automatically Sign up to receive the latest news and ratings for IMAB and its competitors with MarketBeat's FREE daily newsletter. Email Address Obama’s Forever Term [exposed] (Ad)America’s Last Election New documentary, America’s Last Election, reveals the true (and terrifying) story of how the D.C. establishment has engineered a brutal new crisis that could hand them permanent power. Power they will use to reshape America to their dark, dystopian vision. Start streaming it now at no cost here IMAB Media Mentions By Week IMAB Media SentimentLearn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. IMAB News Sentiment▼0.000.73▲Average Medical News Sentiment IMAB News CoverageLearn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. IMAB Articles This Week▼11▲IMAB Articles Average Week Get I-Mab News Delivered to You Automatically Sign up to receive the latest news and ratings for IMAB and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies: Cryoport News Avid Bioservices News IGM Biosciences News Entrada Therapeutics News SIGA Technologies News Y-mAbs Therapeutics News Olema Pharmaceuticals News Travere Therapeutics News Heron Therapeutics News COMPASS Pathways News Headlines Tools: Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:IMAB) was last updated on 6/7/2024 by MarketBeat.com Staff From Our PartnersProtect Your Bank Account Before It’s Too LateFor months I’ve been warning about the federal government’s terrifying new program to control every American’s...Weiss Ratings | SponsoredMillionaire-Making “Wealth Pattern” Just Repeated on April 22If you think you missed out on the Bitcoin band wagon… You need to watch this immediately.Paradigm Press | SponsoredBreaking - The US Gov. Seized CITGODo you want an investment that can double or triple your money in the next three months? The US Court is cu...Augury Research | SponsoredHe Is Giving Away BitcoinAnd my special guest is willing to give you $10 in Bitcoin (BTC) if you take it seriously. Right now is a v...Crypto Swap Profits | SponsoredTop 5 Tech Stocks to Buy for 2024The next evolution of technology is already upending industries worth $7 Trillion… It's already got the world'...Daily Market Alerts | SponsoredTop 5 AI Stocks to Buy for 2024The electric vehicle boom is accelerating – and fast.Market Moving Trends | SponsoredNo Strings Attached: Get 30 Days of Hedgeye’s Top Stock Picks for FreeOptimize your stock investing strategy with Hedgeye's Investing Ideas, where rigorous fundamental stock analys...Hedgeye | SponsoredWas the Great Financial Crisis fun?The Great Financial Crisis, which actually started in the summer of 2007 and did not end until March of 2009, ...Brooks Enterprises | Sponsored